Tang Capital Management SMMT Position
Exited4-Fund ConvergenceTang Capital Management exited their position in Summit Therapeutics Inc. (SMMT) in Q4 2025, after holding the stock for 3 quarters.
The position was first reported in Q2 2025 and has been tracked across 3 quarterly 13F filings.
SMMT is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for AK112 in 29 days (May 15, 2026), making the timing of Tang Capital's position particularly relevant.
Short interest stands at 24.2% of float with 17.2 days to cover, indicating significant bearish positioning against the stock.
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Full company profile →Short Interest
24.2%
17.2 days to cover
Tang Capital Management SMMT Position History
Frequently Asked Questions
Does Tang Capital Management own SMMT?
No. Tang Capital Management exited their position in Summit Therapeutics Inc. (SMMT) in Q4 2025. They previously held the stock for 3 quarters.
How many hedge funds own SMMT?
4 specialist biotech hedge funds currently hold SMMT, including Baker Bros. Advisors, Driehaus Capital, Rock Springs Capital and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Tang Capital Management first buy SMMT?
Tang Capital Management's position in SMMT was first reported in Q2 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Tang Capital Management's SMMT position increasing or decreasing?
Tang Capital Management completely exited their SMMT position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
SMMTCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Tang Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →